XML 84 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Agreements (Details)
 1 Months Ended 12 Months Ended
Oct. 31, 2018
USD ($)
Nov. 30, 2013
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Collaborative Agreements          
Revenue recognized     $ 91,245,000 $ 36,930,000 $ 4,958,000
Deferred reimbursements     10,156,000 14,156,000  
Accounts payable, accrued expenses, and other current liabilities     80,625,000 $ 53,890,000  
Collaborative Arrangements          
Collaborative Agreements          
Payments for collaborative agreement $ 7,000,000        
Conditional aggregate payments per indication $ 86,500,000        
Collaborative Arrangements | GSK          
Collaborative Agreements          
Payments for collaborative agreement     1,300,000    
Revised Agreement | GSK          
Collaborative Agreements          
Upfront payment received   $ 0      
Potential milestone payments upon achievement of post-approval and sales-based milestones   $ 40,000,000      
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones   8      
Revenue recognized     6,900,000    
Deferred reimbursements     15,700,000    
Accounts payable, accrued expenses, and other current liabilities     $ 3,400,000